A. Ingerman

发表

Transurethral evaporation of prostate (TUEP) with Nd:YAG laser using a contact free beam technique: results in 61 patients with benign prostatic hyperplasia.

K. Shinohara, P. Narayan, G. Fournier, 1994, Urology.

Emerging Treatments for Diabetic Macular Edema

A. Ingerman, Daniel Dewey-Mattia, 2010 .

Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

E. Chew, T. Peto, A. Bird, 2015, American journal of ophthalmology.

Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel): Results from a phase I safety trial

E. Chew, T. Peto, A. Bird, 2015 .

Negative repeat transurethral resection of prostate fails to identify patients with stage A1 prostatic carcinoma at lower risk of progression: a long-term study.

P. Carroll, R. Williams, A. Ingerman, 1993, Urology.

Clinical Ophthalmology Dovepress Evaluation of Alcaftadine 0.25% Ophthalmic Solution in Acute Allergic Conjunctivitis at 15 Minutes and 16 Hours after Instillation versus Placebo and Olopatadine 0.1%

J. Greiner, A. Ingerman, Kimberly Edwards-Swanson, 2022 .

Results of a Phase I, Safety, Tolerability, and Bioactivity Study of Intravitreal VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration: The CLEAR-IT 1 Study

P. Campochiaro, J. Cedarbaum, D. Browning, 2007 .

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.

D. Roth, G. Yancopoulos, N. Stahl, 2011, Ophthalmology.

An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema

P. Campochiaro, J. Cedarbaum, D. Browning, 2009, British Journal of Ophthalmology.

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

Quan Dong Nguyen, Ke Yang, David J Browning, 2009, Ophthalmology.

Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.

Quan Dong Nguyen, Ke Yang, G. Yancopoulos, 2011, Ophthalmology.

A Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates

I. Sher, Y. Rotenstreich, M. Lawrence, 2023, Translational vision science & technology.

Results of a Phase I Study of Intravitreal VEGF Trap in Subjects With Diabetic Macular Edema: The CLEAR-IT DME Study

P. Campochiaro, D. Browning, J. Haller, 2007 .

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.

D. Roth, G. Yancopoulos, N. Stahl, 2011, Ophthalmology.

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

P. Campochiaro, P. Kaiser, J. Slakter, 2009, Ophthalmology.